Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review.

[1]  R. Bindra,et al.  Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma , 2022, Scientific Reports.

[2]  Ella L. Kim,et al.  Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression , 2022, Cell Death & Disease.

[3]  Tao Jiang,et al.  Comprehensive transcriptomic characterization reveals core genes and module associated with immunological changes via 1619 samples of brain glioma , 2021, Cell Death & Disease.

[4]  M. Wolter,et al.  The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma , 2021, Cell Death & Disease.

[5]  Xu Hou,et al.  Clinical Value of TXNDC12 Combined With IDH and 1p19q as Biomarkers for Prognosis of Glioma , 2021, Pathology & Oncology Research.

[6]  Tao Jiang,et al.  Tumor microenvironment is associated with clinical and genetic properties of diffuse gliomas and predicts overall survival , 2021, Cancer Immunology, Immunotherapy.

[7]  M. Sorokin,et al.  Algorithmically Deduced FREM2 Molecular Pathway Is a Potent Grade and Survival Biomarker of Human Gliomas , 2021, Cancers.

[8]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[9]  Hui Cao,et al.  A comprehensive prognostic signature for glioblastoma patients based on transcriptomics and single cell sequencing , 2021, Cellular Oncology.

[10]  Dorela D. Shuboni-Mulligan,et al.  Association of Circadian Clock Gene Expression with Glioma Tumor Microenvironment and Patient Survival , 2021, Cancers.

[11]  K. Aldape,et al.  Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma , 2021, Neuro-oncology.

[12]  M. Snuderl,et al.  Molecular Signatures of Chromosomal Instability Correlate With Copy Number Variation Patterns and Patient Outcome in IDH-Mutant and IDH-Wildtype Astrocytomas. , 2021, Journal of neuropathology and experimental neurology.

[13]  K. Aldape,et al.  Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations , 2021, Acta Neuropathologica.

[14]  Wei-wei Wang,et al.  Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas , 2021, Modern Pathology.

[15]  B. Pang,et al.  Abnormal expression of HOXD11 promotes the malignant behavior of glioma cells and leads to poor prognosis of glioma patients , 2021, PeerJ.

[16]  Han Yan,et al.  TEAD4 is a novel independent predictor of prognosis in LGG patients with IDH mutation , 2021, Open life sciences.

[17]  Yanyan Ping,et al.  Prognostic impact of a lymphocyte activation-associated gene signature in GBM based on transcriptome analysis , 2020, PeerJ.

[18]  Caicun Zhou,et al.  Alterations of DNA damage repair in cancer: from mechanisms to applications , 2020, Annals of translational medicine.

[19]  Xin Yang,et al.  A Novel Four-Gene Signature Associated With Immune Checkpoint for Predicting Prognosis in Lower-Grade Glioma , 2020, Frontiers in Oncology.

[20]  M. Fassan,et al.  Mismatch-Repair Protein Expression in High-Grade Gliomas: A Large Retrospective Multicenter Study , 2020, International journal of molecular sciences.

[21]  A. Di Leonardo,et al.  P14ARF: The Absence that Makes the Difference , 2020, Genes.

[22]  Kuanyu Wang,et al.  A novel DNA damage response signature of IDH-mutant grade II and grade III astrocytoma at transcriptional level , 2020, Journal of Cancer Research and Clinical Oncology.

[23]  P. Lowenstein,et al.  Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1 , 2020, Neuro-oncology advances.

[24]  Wei Jiang,et al.  Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer. , 2019, Seminars in cancer biology.

[25]  G. Hoxhaj,et al.  The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism , 2019, Nature Reviews Cancer.

[26]  Tao Jiang,et al.  Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma. , 2019, Carcinogenesis.

[27]  G. Reifenberger,et al.  FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas , 2019, Acta Neuropathologica.

[28]  F. Ducray,et al.  PL1.1 CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas , 2019, Neuro-Oncology.

[29]  M. Snuderl,et al.  Total copy number variation as a prognostic factor in adult astrocytoma subtypes , 2019, Acta Neuropathologica Communications.

[30]  Fan Wu,et al.  Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma , 2019, Cancer Cell International.

[31]  Zheng Zhao,et al.  Molecular classification of IDH-mutant glioblastomas based on gene expression profiles , 2019, Carcinogenesis.

[32]  M. Kool,et al.  Integrated molecular characterization of IDH‐mutant glioblastomas , 2018, Neuropathology and applied neurobiology.

[33]  Huimin Hu,et al.  ADAR3 expression is an independent prognostic factor in lower-grade diffuse gliomas and positively correlated with the editing level of GRIA2Q607R , 2018, Cancer Cell International.

[34]  S. Goel,et al.  CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest. , 2018, Trends in cell biology.

[35]  A. Unterberg,et al.  Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma , 2018, International journal of molecular sciences.

[36]  Ming-Rong Wang,et al.  Overexpression of MCM6 predicts poor survival in patients with glioma. , 2018, Human pathology.

[37]  Zheng Zhao,et al.  Expression profile analysis of antisense long non-coding RNA identifies WDFY3-AS2 as a prognostic biomarker in diffuse glioma , 2018, Cancer Cell International.

[38]  David T. W. Jones,et al.  Novel, improved grading system(s) for IDH-mutant astrocytic gliomas , 2018, Acta Neuropathologica.

[39]  M. J. van den Bent,et al.  Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma , 2018, Journal of Neuro-Oncology.

[40]  T. Mikkelsen,et al.  A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence , 2018, Cell reports.

[41]  H. Noushmehr,et al.  Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications. , 2018, Neuro-oncology.

[42]  I. Rogozin,et al.  Diverse roles of RAD18 and Y-family DNA polymerases in tumorigenesis , 2018, Cell cycle.

[43]  L. Huang,et al.  Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma. , 2018, Journal of neurosurgery.

[44]  Hideo Nakamura,et al.  Prognostic relevance of genetic alterations in diffuse lower-grade gliomas , 2018, Neuro-oncology.

[45]  Johan Lennartsson,et al.  The PDGF/PDGFR pathway as a drug target. , 2017, Molecular aspects of medicine.

[46]  H. Kurahashi,et al.  Remote intracranial recurrence of IDH mutant gliomas is associated with TP53 mutations and an 8q gain , 2017, Oncotarget.

[47]  A. Wu,et al.  Expression and prognostic value of microRNAs in lower-grade glioma depends on IDH1/2 status , 2017, Journal of Neuro-Oncology.

[48]  A. Wu,et al.  Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses , 2016, Molecular Neurobiology.

[49]  R. Stupp,et al.  PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status , 2016, Oncotarget.

[50]  M. Sanson,et al.  Chromosome 17p Homodisomy Is Associated With Better Outcome in 1p19q Non-Codeleted and IDH-Mutated Gliomas. , 2016, The oncologist.

[51]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[52]  Steven J. M. Jones,et al.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.

[53]  I. Mellinghoff,et al.  Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer , 2016, Clinical Cancer Research.

[54]  P. Jeggo,et al.  DNA repair, genome stability and cancer: a historical perspective , 2015, Nature Reviews Cancer.

[55]  M. J. van den Bent,et al.  PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients , 2015, Acta Neuropathologica Communications.

[56]  Arie Perry,et al.  CDKN2A Loss Is Associated With Shortened Overall Survival in Lower-Grade (World Health Organization Grades II–III) Astrocytomas , 2015, Journal of neuropathology and experimental neurology.

[57]  Eric O'Neill,et al.  PI3K/Akt-mediated regulation of p53 in cancer. , 2014, Biochemical Society transactions.

[58]  K. Hoang-Xuan,et al.  Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas. , 2014, Neuro-oncology.

[59]  Aubry K. Miller,et al.  D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma , 2014, Acta neuropathologica communications.

[60]  L. Mariani,et al.  MET Gain in Diffuse Astrocytomas is Associated with Poorer Outcome , 2013, Brain pathology.

[61]  Karsten Wrede,et al.  DMBT1 Homozygous Deletion in Diffuse Astrocytomas Is Associated With Unfavorable Clinical Outcome , 2012, Journal of neuropathology and experimental neurology.

[62]  Bin Wang,et al.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.

[63]  Yi Zhang,et al.  Active DNA demethylation: many roads lead to Rome , 2010, Nature Reviews Molecular Cell Biology.

[64]  Yi Zhang,et al.  Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification , 2010, Nature.

[65]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[66]  T. Halazonetis,et al.  Genomic instability — an evolving hallmark of cancer , 2010, Nature Reviews Molecular Cell Biology.

[67]  V. Corces,et al.  CTCF: Master Weaver of the Genome , 2009, Cell.

[68]  David R. Liu,et al.  Conversion of 5-Methylcytosine to 5- Hydroxymethylcytosine in Mammalian DNA by the MLL Partner TET1 , 2009 .

[69]  A. Arcaro,et al.  The Phosphoinositide 3-Kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic Implications , 2007, Current genomics.

[70]  C. Marshall,et al.  How do small GTPase signal transduction pathways regulate cell cycle entry? , 1999, Current opinion in cell biology.

[71]  John Calvin Reed,et al.  Regulation of cell death protease caspase-9 by phosphorylation. , 1998, Science.

[72]  G. Peters,et al.  The p16INK4a/CDKN2A tumor suppressor and its relatives. , 1998, Biochimica et biophysica acta.

[73]  N. Dyson.  The regulation of E2F by pRB-family proteins. , 1998, Genes & development.